AlphAIAlphAI — Financial news for AI agents
tradingview.com$HIMS

Hims & Hers Health, Inc. (HIMS) Q3 Revenue Grew 49% Year Over Year

Hims & Hers Health reported Q3 2026 revenue growth of 49% YoY, with U.S. and international revenues up 21% and over 300%, respectively. The company cited two consecutive quarters of accelerating growth, but provided no financial outlook.

Original reporting
tradingview.com
Published Nov 9, 2026, 9:05 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 9, 2026, 9:08 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Hims & Hers Health, Inc. (HIMS) Q3 Revenue Grew 49% Year Over Year — source image
Source · tradingview.com
Decision brief

The 30-second read

$HIMSBullishMed
01

Why it matters

The 49% YoY revenue increase is a fresh, material data point that could influence investor sentiment and price action.

02

Market read

First‑time disclosure of strong top‑line growth makes the news relevant for traders monitoring telehealth stocks.

03

What to watch

Potential regulatory scrutiny of telehealth services could temper upside.

Relevance 7/10Novelty 7/10Timing: post‑market today

Background

The article summarizes Hims & Hers Health's Q3 revenue figures released via a BusinessWire press release.

Company-level read

Ticker impact

$HIMSBullishHigh confidence
Context

Hims & Hers Health reported Q3 2026 revenue up 49% YoY, with U.S. revenue up 21% and international revenue up over 300%.

Expected impact

likely upward as investors price in the robust top‑line growth

Evidence & confidence

Revenue acceleration is a material earnings metric; the first report of such growth typically drives buying pressure.

Market effects

Sector

Telehealth and digital health sector may see broader optimism from HIMS's growth.

Regional

U.S. and international markets could react positively to the strong international revenue surge.

Global

Highlights growing demand for virtual health services worldwide.

Counterpoint

What could challenge this read

Revenue growth may not translate into profitability if cost structure remains high.

Key entities

  • company
    Hims & Hers Health, Inc.

    U.S. telehealth provider reporting Q3 2026 results.

Read at source← All news

StoryHims & Hers posts 49% revenue growth but margin collapse and cuts 2026 guidance

Also covered by

4 outlets

Related articles

$HIMSMed

HIMS May See Heightened ‘Gyrations’ As Weight-Loss Drug Trends Fuel Subscriber Uncertainty, Jefferies Warns – Stock Hits 7-Month Lows

Hims & Hers Health (HIMS) shares fell 15% after Q3 earnings missed expectations, with subscribers declining sequentially. Jefferies lowered its price target to $24, citing volatility from weight-loss drug trends. Needham reduced its target to $32 but kept a 'Buy' rating. The company reported a Q3 loss and cut its FY2026 EBITDA and revenue guidance.

finance.yahoo.com
$HIMSHighAI 8/10

Hims & Hers Stock Falls 15% on Weak Q4 Revenue Outlook

Hims & Hers Health (HIMS) shares dropped 15% after the company issued Q4 revenue guidance below expectations, forecasting $875M–$895M vs. analysts' $955.1M estimate. Q3 revenue grew 49% to $890.4M but gross margin declined to 57% from 74%. The company also faces regulatory challenges over weight-loss medications and data privacy.

grafa.com
$HIMSHighAI 8/10

Hims & Hers cuts 2026 earnings outlook despite 49% revenue growth

Hims & Hers Health (HIMS) reported 49% revenue growth in Q3, but lowered its 2026 adjusted EBITDA forecast to $257M-$277M. Revenue guidance was tightened to $3.13B-$3.15B, with Q4 sales expected at $875M-$895M. International revenue surged 321%, while gross margin contracted to 57% from 74%. The company reported a net loss of $33M, with adjusted EBITDA margin falling to 9% from 13%.

finance.yahoo.com